中华中医药学刊

目的 评价宣肺止嗽合剂治疗新型冠状病毒感染(简称新冠感染)咳嗽(风邪犯肺证)的临床疗效。方法 采用多中心、前瞻性、平行对照的临床研究方法，纳入新型冠状病毒感染具有咳嗽症状证属风邪犯肺证的患者，分为对照组及试验组，对照组予常规新型冠状病毒感染治疗，试验组加用宣肺止嗽合剂，疗程7 d。比较两组咳嗽视觉模拟(VAS)评分、咳嗽缓解和消失情况及用药安全性。结果 154例受试者纳入研究，其中试验组116例，对照组38例。治疗后第7天，两组咳嗽VAS评分较治疗前显著下降(P<0.01),且试验组显著低于对照组(P<0.01)。试验组咳嗽缓解率、咳嗽消失率均高于对照组，中位咳嗽缓解时间显著短于对照组(P<0.01)。研究过程中无不良反应事件发生。结论 新冠感染咳嗽(风邪犯肺证)患者在常规治疗基础上联合宣肺止嗽合剂，可有效改善咳嗽症状，且具有较高的安全性。

Objective To evaluate the clinical efficacy of Xuanfei Zhisou Mixture(宣肺止嗽合剂) for cough(wind evil invading lung syndrome) caused by corona virus disease 2019(COVID-19). Methods A multi-center, prospective, parallel controlled methods control method was used. The COVID-19 patients with cough(wind evil invading lung syndrome) were enrolled and divided into treatment group and control group. The control group received routine treatment for COVID-19 and the treatment group received Xuanfei Zhisou Mixture additionally for 7 days. The cough visual analogue scale(VAS),cough relief and disappearance and safety were compared. Results A total of 154 subjects were included in this study, with 116 cases in treatment group and 38 cases in control group. After 7-day treatment, when compared with those before treatment, cough VAS score decreased in both groups, and the score in the treatment group decreased greatly than that in the control group(P<0.01). Compared with those in the control group, the cough relief rate and disappearance rate were higher, and the median time of cough relief was lower. No adverse reactions occurred during the research process. Conclusion Xuanfei Zhisou Mixture combined with usual treatment could safely and effectively alleviate clinical symptoms of cough(wind evil invading lung syndrome) caused by COVID-19.